Drug Profile

Research programme: CAR-natural killer cell therapies - Avalon GloboCare

Alternative Names: CAR-NK therapies - Avalon Globocare

Latest Information Update: 22 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avalon GloboCare
Developer Avalon GloboCare; AVAR BioTherapeutics
Class CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 Apr 2025 Avalon GloboCare and Arbele has patent protection for CAR-T and CAR-NK Cell Technology in China
18 Feb 2025 Avalon GloboCare receives patent allowance for CAR-T and CAR-NK Cell Technology in China
28 Feb 2023 No recent reports of development identified for research development in Cancer in China (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com